Terms: = Lung cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7 AND Treatment
46 results:
1. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
[TBL] [Abstract] [Full Text] [Related]
2. Identifying genes associated with resistance to KRAS G12C inhibitors via machine learning methods.
Lin X; Ma Q; Chen L; Guo W; Huang Z; Huang T; Cai YD
Biochim Biophys Acta Gen Subj; 2023 Dec; 1867(12):130484. PubMed ID: 37805078
[TBL] [Abstract] [Full Text] [Related]
3. Menin-mll1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract] [Full Text] [Related]
4. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and kmt2a-rearranged AML.
Menghrajani K; Gomez-Arteaga A; Madero-Marroquin R; Zhang MJ; Bo-Subait K; Sanchez J; Wang HL; Aljurf M; Assal A; Bacher VU; Badawy SM; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Castillo P; Cerny J; Chhabra S; Ciurea SO; DeFilipp Z; Farhadfar N; Gadalla S; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt G; Kanakry CG; Kansagra A; Khimani F; Krem M; Lazarus H; Liu H; Martino R; Michelis FV; Nathan S; Nishihori T; Olsson R; Reshef R; Rizzieri D; Rowe JM; Savani BN; Seo S; Sharma A; Solh M; Ustun C; Verdonck LF; Hourigan C; Sandmaier B; Litzow M; Kebriaei P; Weisdorf D; Zhang Y; Tallman MS; Saber W
Blood Adv; 2022 Jan; 6(3):828-847. PubMed ID: 34551064
[TBL] [Abstract] [Full Text] [Related]
5. Ceramide induces the apoptosis of non‑small cell lung cancer cells through the Txnip/trx1 complex.
Shi Y; Jin Y; Liu F; Jiang J; Cao J; Lu Y; Yang J
Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33760130
[TBL] [Abstract] [Full Text] [Related]
6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract] [Full Text] [Related]
7. Impact of Multimodality treatment Sequence on Survival in Stage IIB Non-Small Cell lung cancer.
Stokes SM; Massarweh NN; Stringham JR; Varghese TK
Ann Thorac Surg; 2021 Nov; 112(5):1559-1567. PubMed ID: 33352174
[TBL] [Abstract] [Full Text] [Related]
8. Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial.
Korfage IJ; Carreras G; Arnfeldt Christensen CM; Billekens P; Bramley L; Briggs L; Bulli F; Caswell G; Červ B; van Delden JJM; Deliens L; Dunleavy L; Eecloo K; Gorini G; Groenvold M; Hammes B; Ingravallo F; Jabbarian LJ; Kars MC; Kodba-Čeh H; Lunder U; Miccinesi G; Mimić A; Ozbič P; Payne SA; Polinder S; Pollock K; Preston NJ; Seymour J; Simonič A; Thit Johnsen A; Toccafondi A; Verkissen MN; Wilcock A; Zwakman M; van der Heide A; Rietjens JAC
PLoS Med; 2020 Nov; 17(11):e1003422. PubMed ID: 33186365
[TBL] [Abstract] [Full Text] [Related]
9. Menin‑mll inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract] [Full Text] [Related]
10. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
11. [
Guo T; Dong X; Shi G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):551-555. PubMed ID: 30378308
[TBL] [Abstract] [Full Text] [Related]
12. Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.
Abrams T; Connor A; Fanton C; Cohen SB; Huber T; Miller K; Hong EE; Niu X; Kline J; Ison-Dugenny M; Harris S; Walker D; Krauser K; Galimi F; Wang Z; Ghoddusi M; Mansfield K; Lee-Hoeflich ST; Holash J; Pryer N; Kluwe W; Ettenberg SA; Sellers WR; Lees E; Kwon P; Abraham JA; Schleyer SC
Clin Cancer Res; 2018 Sep; 24(17):4297-4308. PubMed ID: 29764854
[No Abstract] [Full Text] [Related]
13. Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.
Lu H; Yang S; Zhu H; Tong X; Xie F; Qin J; Han N; Wu X; Fan Y; Shao YW; Mao W
BMC Cancer; 2018 Mar; 18(1):251. PubMed ID: 29506494
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
[TBL] [Abstract] [Full Text] [Related]
15. β-Sitosterol targets Trx/trx1 reductase to induce apoptosis in A549 cells via ROS mediated mitochondrial dysregulation and p53 activation.
Rajavel T; Packiyaraj P; Suryanarayanan V; Singh SK; Ruckmani K; Pandima Devi K
Sci Rep; 2018 Feb; 8(1):2071. PubMed ID: 29391428
[TBL] [Abstract] [Full Text] [Related]
16. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells.
Zheng X; Xu W; Sun R; Yin H; Dong C; Zeng H
Chem Biol Interact; 2017 Sep; 275():74-85. PubMed ID: 28757135
[TBL] [Abstract] [Full Text] [Related]
17. WDR5 positively regulates p53 stability by inhibiting p53 ubiquitination.
Xie Q; Li Z; Chen J
Biochem Biophys Res Commun; 2017 May; 487(2):333-338. PubMed ID: 28412363
[TBL] [Abstract] [Full Text] [Related]
18. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.
Chen J; Solomides C; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2017 Feb; 79(2):369-380. PubMed ID: 28120035
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD.
Kang HS; Rhee CK; Kim SK; Kim JW; Lee SH; Yoon HK; Ahn JH; Kim YH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2467-2473. PubMed ID: 27757029
[TBL] [Abstract] [Full Text] [Related]
20. [Survival analysis of surgically treated renal cell carcinoma: an analysis of 10-year data from single center].
Zhang YS; Yu HY; Dong F; Li HZ
Zhonghua Wai Ke Za Zhi; 2016 Jul; 54(7):528-33. PubMed ID: 27373480
[TBL] [Abstract] [Full Text] [Related]
[Next]
